Haemonetics Corporation (HAE) SEC Filings & Earnings Calls

Rollout scope and timing subject to change; implementation details still to be determined.

“The scope and timing of the rollout remain subject to change consistent with the terms of the supply agreement, and the implementation details for the rollout are still to be determined by CSL and the Company.” · word for word

No minimum purchase commitments; scope and timing of implementation not determined.

“does not contain minimum purchase commitments ... scope and timing of implementation have not yet been determined”

Debt repayment burden

“During the first quarter of fiscal 2027, we repaid $50.0 million of the outstanding amount under the revolving credit facility. As of June 27, 2026, $250.0 million remained outstanding under the revolving credit facility.” · word for word

Interest expense increase

“Interest and other expense, net increased by $1.2 million during the three months ended June 27, 2026, as compared with the same period of fiscal 2026. The increase was primarily due to increase interest expense resulting from the borrowing of the revolving credit facility” · word for word

Effective tax rate increase

“The increase in the reported tax rate for the three months ended June 27, 2026, compared to the same period in fiscal 2026, relates primarily to the increase in net stock compensation shortfalls and the impact of losses incurred in certain jurisdictions for which no tax benefit was recognized.” · word for word

Operating expense growth outpacing revenue growth, pressuring margins

“Operating expenses up 5.0% vs revenue up 5.6%; adjusted operating margin down 70 bps”

Higher effective tax rate due to stock compensation shortfalls and valuation allowances

“Effective tax rate 30.6% vs 24.7% prior year; adjusted rate 25.7% vs 24.9%”

Potential dilution from additional authorized shares under LTIP.

“4,680,000 additional shares authorized for issuance under Amended Plan.”

Interventional Technologies competitive pressure

“In Interventional Technologies, we addressed near-term challenges driven by competitive dynamics and evolving electrophysiology trends through targeted commercial measures and operational improvements, positioning the portfolio for a return to growth in future periods.” · word for word

Share price decline despite financial performance

“Despite Haemonetics' financial and strategic achievements in fiscal 2026, our share price performance declined as we navigated external market challenges and macroeconomic uncertainties: One-Year Cumulative Total Shareholder Return (Fiscal 2026) $86 (from $100 investment).” · word for word

Customer Concentration in Plasma

“Approximately 44% of our revenue during fiscal 2026 was generated by our ten largest customers.” · word for word

Goodwill Impairment Risk - Interventional Technologies

“The fair value of the Interventional Technologies reporting unit... only exceeded its carrying value by 6%.” · word for word

Intangible Asset Impairment - Attune Medical

“Recognized impairment of intangible assets of $86.5 million... related to the Attune Medical asset group.” · word for word

EU MDR Compliance Costs

“Complying with the requirements of these regulations has and will continue to require us to incur significant expenditures.” · word for word

Tariff Impact on Costs

“The increase in fiscal 2026 was primarily due to costs associated with the acquisition of Vivasure, impacts from tariffs and higher performance-based compensation costs.” · word for word

Impairment of intangible assets related to Attune Medical led to GAAP operating loss.

“operating losses of $23.0 million and a (6.6)% operating margin in the fourth quarter of fiscal 2026, compared with operating income of $71.3 million” · word for word

Debt repayment funded partly by revolver borrowings, increasing leverage.

“funded with cash on hand and borrowings under the Company’s revolving credit facility” · word for word

Revenue decline in Blood Center due to divestiture; Hospital segment flat.

“Blood Center revenue down 19.6% due to Whole Blood divestiture; Hospital down 0.3%.”

Customer concentration risk

“The decrease during the nine months ended December 27, 2025, was driven by lower sales volumes in North America, primarily relating to the previously announced customer transition of CSL Plasma, which was partially offset by prior innovation benefits, share gains and upfront revenue recognition on execution of a renegotiated long-term software agreement with” · word for word

Divestiture impact

“The decrease was primarily driven by the divestiture of our Whole Blood product line, which was completed in January 2025, partially offset by product mix.” · word for word

Impairment of intangible assets

“We recognized impairment charges of intangible assets of $0.7 million and $9.3 million, respectively, during the three and nine months ended December 27, 2025, as compared with no impairment and $2.4 million, respectively, during the three and nine months ended December 28, 2024. The impairment charges in fiscal 2026 were related to the intellectual property” · word for word

Integration risk and contingent consideration exposure up to €85M based on sales milestones.

“Up to €85M in contingent consideration based on sales growth and milestones.”

Customer concentration risk (CSL Plasma)

“We do not expect any North America disposable sales to CSL Plasma in fiscal 2026.” · word for word

Impairment of intangible assets

“We recognized impairment charges of intangible assets of $8.6 million during both the three and six months ended September 27, 2025, as compared with $2.4 million during both the three and six months ended September 28, 2024.” · word for word

CSL transition continues to impact Plasma revenue, though organic ex-CSL growth is strong.

“Plasma revenue -9.5% reported, but organic ex-CSL +18.6%.”

Blood Center segment revenue decline of 17.6% reported, though organic growth is slightly positive at 3.9%.

“Blood Center revenue $56.5M, (17.6)% reported, organic 3.9%.”